<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268500</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0656</org_study_id>
    <nct_id>NCT02268500</nct_id>
  </id_info>
  <brief_title>VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)</brief_title>
  <acronym>VACC-HeFT</acronym>
  <official_title>VAccination to Improve Clinical outComes in Heart Failure Trial (VACC-HeFT): a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, prospective, randomized, open-label blinded-endpoint trial in patients with&#xD;
      heart failure will be conducted; 20 will be assigned to the standard dose vaccine dose and 20&#xD;
      patients to high dose influenza vaccine. Post-vaccine antibody measurements will be assessed,&#xD;
      as well as tolerability differences between groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, active-control trial of high dose influenza vaccine&#xD;
      compared to standard dose influenza vaccine for one season in adult participants with&#xD;
      symptomatic heart failure(HF). The primary outcome measure is humoral (antibody-mediated)&#xD;
      immune response, and secondary outcomes include cumulative incidence of influenza-like&#xD;
      illness symptoms and all cause hospitalizations. The aim is to gather information on&#xD;
      feasibility of this study design and effect size differences to inform a larger&#xD;
      outcomes-based clinical trial.&#xD;
&#xD;
      The 5.8 million Individuals in the US with heart HF are at high risk for influenza infection&#xD;
      and associated morbidity, mortality and increased health care costs despite annual influenza&#xD;
      vaccination. Higher dose of vaccine is approved for use in older adults. Antibody-mediated&#xD;
      immunity contributes to vaccine-induced protection from influenza illness. Investigators at&#xD;
      University of Wisconsin(UW) Madison have demonstrated reduced antibody titers to influenza&#xD;
      vaccination in patients with HF. Additionally, study team has shown in a pilot study that&#xD;
      double dose influenza vaccine resulted in increased titers and was well tolerated.&#xD;
&#xD;
      A multi-center, prospective, randomized, open-label blinded-endpoint trial will be conducted&#xD;
      with 20 participants assigned to the standard dose vaccine dose and 20 participants to high&#xD;
      dose influenza vaccine. The primary outcome measure is the rate of seroconversion (4-fold&#xD;
      rise in antibody titers to A/H3N2, A/H1N1, and B-type vaccine antigens), assessed 4 weeks&#xD;
      post vaccination. The study will also examine feasibility differences in symptoms of&#xD;
      influenza and all-cause hospitalizations between vaccine dose groups, and these data will be&#xD;
      used for planning a subsequent outcomes-based clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H1N1 Vaccine Antigens</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H3N2 Vaccine Antigens</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With 4 Fold Rise in Serum Antibody Concentration of B-type Vaccine Antigens</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Influenza Like Illness</measure>
    <time_frame>8 months</time_frame>
    <description>Influenza Like Illness is not considered adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All-cause Hospitalizations</measure>
    <time_frame>8 months</time_frame>
    <description>All-cause hospitalizations are not considered adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Standard dose influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dose (45ug) influenza vaccine will be administered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose (180ug) influenza vaccine will be administered intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>Influenza vaccine</description>
    <arm_group_label>High dose influenza vaccine</arm_group_label>
    <arm_group_label>Standard dose influenza vaccine</arm_group_label>
    <other_name>Fluzone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults &gt; 18 years old&#xD;
&#xD;
          2. Able to give informed consent&#xD;
&#xD;
          3. Systolic or diastolic dysfunction&#xD;
&#xD;
          4. Previously or currently symptomatic heart failure&#xD;
&#xD;
          5. Stable on current heart failure drug therapy regimen for &gt; 30 days and no change in&#xD;
             heart failure drug therapy regimen on day of enrollment&#xD;
&#xD;
          6. Hospitalization (for any reason) in last 12 months&#xD;
&#xD;
          7. Received influenza vaccination the prior season&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergic reaction or adverse event to influenza vaccine&#xD;
&#xD;
          2. Documented severe allergy to egg products&#xD;
&#xD;
          3. Unwilling or unable to give consent&#xD;
&#xD;
          4. Moderate to severe acute febrile illness at baseline&#xD;
&#xD;
          5. Immunologic conditions that may affect immune responses per clinical judgment of the&#xD;
             investigators&#xD;
&#xD;
          6. Use of immunosuppressants or immunomodulating therapies within 3 months of the study,&#xD;
             including prednisone, cyclosporine, tacrolimus, methotrexate, azathioprine,&#xD;
             mycophenolate mofetil, cyclophosphamide, and injectable interferons&#xD;
&#xD;
          7. Participation in a clinical trial within 30 days&#xD;
&#xD;
          8. Absence for more than 7 consecutive days during the surveillance period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orly Vardeny, PharmD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 8, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <results_first_submitted>April 28, 2021</results_first_submitted>
  <results_first_submitted_qc>June 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2021</results_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Dose Influenza Vaccine</title>
          <description>Standard dose (45ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
        </group>
        <group group_id="P2">
          <title>High Dose Influenza Vaccine</title>
          <description>High dose (180ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Dose Influenza Vaccine</title>
          <description>Standard dose (45ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
        </group>
        <group group_id="B2">
          <title>High Dose Influenza Vaccine</title>
          <description>High dose (180ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="12.2"/>
                    <measurement group_id="B2" value="62.5" spread="13.1"/>
                    <measurement group_id="B3" value="59.45" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF) percentage</title>
          <units>percentage of ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="9.8"/>
                    <measurement group_id="B2" value="40.3" spread="10.2"/>
                    <measurement group_id="B3" value="39.55" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.7" spread="10"/>
                    <measurement group_id="B2" value="30.9" spread="6.8"/>
                    <measurement group_id="B3" value="32.3" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>number of current tobacco users</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with Diabetes mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with Atrial fibrillation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with Ischemic etiology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspirin users</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) users</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta blocker users</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mineralocorticoid Receptor Antagonists (MRA) users</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diuretic users</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Long acting nitrate users</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Digoxin users</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H1N1 Vaccine Antigens</title>
        <time_frame>4 weeks</time_frame>
        <population>1 participant from 'standard dose influenza vaccine' arm and 1 participant from 'high dose influenza vaccine' arm were excluded as the sample was inadequate to run the assay.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine</title>
            <description>Standard dose (45ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>High Dose Influenza Vaccine</title>
            <description>High dose (180ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H1N1 Vaccine Antigens</title>
          <population>1 participant from 'standard dose influenza vaccine' arm and 1 participant from 'high dose influenza vaccine' arm were excluded as the sample was inadequate to run the assay.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H3N2 Vaccine Antigens</title>
        <time_frame>4 weeks</time_frame>
        <population>1 participant from 'standard dose influenza vaccine' arm and 1 participant from 'high dose influenza vaccine' arm were excluded as the sample was inadequate to run the assay.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine</title>
            <description>Standard dose (45ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>High Dose Influenza Vaccine</title>
            <description>High dose (180ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H3N2 Vaccine Antigens</title>
          <population>1 participant from 'standard dose influenza vaccine' arm and 1 participant from 'high dose influenza vaccine' arm were excluded as the sample was inadequate to run the assay.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 4 Fold Rise in Serum Antibody Concentration of B-type Vaccine Antigens</title>
        <time_frame>4 weeks</time_frame>
        <population>1 participant from 'standard dose influenza vaccine' arm and 1 participant from 'high dose influenza vaccine' arm were excluded as the sample was inadequate to run the assay.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine</title>
            <description>Standard dose (45ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>High Dose Influenza Vaccine</title>
            <description>High dose (180ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 4 Fold Rise in Serum Antibody Concentration of B-type Vaccine Antigens</title>
          <population>1 participant from 'standard dose influenza vaccine' arm and 1 participant from 'high dose influenza vaccine' arm were excluded as the sample was inadequate to run the assay.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Influenza Like Illness</title>
        <description>Influenza Like Illness is not considered adverse event.</description>
        <time_frame>8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine</title>
            <description>Standard dose (45ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>High Dose Influenza Vaccine</title>
            <description>High dose (180ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Influenza Like Illness</title>
          <description>Influenza Like Illness is not considered adverse event.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All-cause Hospitalizations</title>
        <description>All-cause hospitalizations are not considered adverse events.</description>
        <time_frame>8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine</title>
            <description>Standard dose (45ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>High Dose Influenza Vaccine</title>
            <description>High dose (180ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All-cause Hospitalizations</title>
          <description>All-cause hospitalizations are not considered adverse events.</description>
          <units>hospitalizations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week</time_frame>
      <desc>1 week post randomization, participants were contacted by phone for ascertainment of injection related adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Dose Influenza Vaccine</title>
          <description>Standard dose (45ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
        </group>
        <group group_id="E2">
          <title>High Dose Influenza Vaccine</title>
          <description>High dose (180ug) influenza vaccine will be administered intramuscularly&#xD;
Influenza vaccine: Influenza vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Orly Vardeny, Associate Professor of Medicine</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612.467.4586</phone>
      <email>ovardeny@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

